Business Context and Reporting Period
This Form 8-K is filed by Enochian Biosciences Inc. (trading symbol: ENOB) on November 30, 2022, reporting events occurring on November 23, 2022. The filing addresses regulatory compliance issues regarding the timely submission of periodic financial reports to the Securities and Exchange Commission (SEC) and The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory status and reporting deadlines rather than financial performance data.
Material Changes and Compliance Status
- Delisting Notice: On November 23, 2022, the Company received a notice from Nasdaq stating it remains in non-compliance with Listing Rule 5250(c)(1) due to the failure to file its Quarterly Report on Form 10-Q for the period ended September 30, 2022.
- Prior Non-Compliance: This follows a previous notice dated October 17, 2022, regarding the failure to timely file the Annual Report on Form 10-K for the period ended June 30, 2022.
- Immediate Effect: The notice has no immediate effect on the listing of the Company's shares; however, failure to regain compliance will result in delisting.
Outlook, Risks, and Contingencies
- Compliance Timeline: The Company has 60 calendar days from the Form 10-K due date (until December 16, 2022) to submit a plan to regain compliance to Nasdaq.
- Extension Possibility: If Nasdaq accepts the plan, the Company may be granted up to 180 calendar days from the Form 10-K due date (until April 11, 2023) to regain compliance.
- Appeal Rights: If the plan is rejected, the Company has the opportunity to appeal the decision to a Nasdaq Hearings Panel.
- Primary Risk: The primary risk identified is the potential delisting of common stock from The Nasdaq Stock Market LLC if compliance is not restored within the specified grace periods.
Investor Verification Checklist
- Verify the current filing status of the Form 10-Q for the period ended September 30, 2022, and the Form 10-K for the period ended June 30, 2022.
- Monitor whether the Company submits a compliance plan to Nasdaq by the December 16, 2022 deadline.
- Check for any subsequent Nasdaq communications regarding the acceptance or rejection of the compliance plan.
- Review the attached press release (Exhibit 99.1) for any additional management commentary not included in the 8-K text.